August 29, 2005 -- Novavax led the list of biotech stocks higher today, continuing to trade up on news of its vaccine with a new mechanism, Biosite gained on expanded use for its test for heart attack risk, Novartis won priority review for the use of Femara to prevent a recurrence of breast cancer, MedImmune licensed the rights to GlaxoSmithKline’s anti-staphylococcal antibody program, Eisai Company touted the Phase II results of its sepsis treatment, and Immunicon laid off 25% of its staff to conserve cash. Overall, biotech traded higher today, with the Centient Biotech 200 moving up more than 40 points or 1.09%, the largest increase in almost 3 weeks. More details...
